ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 331,31
-0,88%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. vTv Therapeutics Inc (VTVT)

  7. vTv Therapeutics Inc (VTVT) Actualités

VTVT vTv Therapeutics Inc

23,63
-0,0699 (-0,29%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
vTv Therapeutics Inc VTVT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0699 -0,29% 23,63 06:00:09
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
22,85 22,5001 24,33 23,63 23,6999
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
19/3/202413:30PRNUSCANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA..
13/3/202413:00GLOBEvTv Therapeutics Announces 2023 Fourth Quarter and Full Year..
07/3/202422:47EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/3/202401:52EDGAR2Form SC 13D - General statement of acquisition of beneficial..
05/3/202414:04EDGAR2Form 8-K - Current report
04/3/202414:00GLOBEvTv Therapeutics Announces FDA Submission for First Phase 3..
01/3/202414:00GLOBEvTv Therapeutics to Participate at the TD Cowen 44th Annual..
28/2/202415:26EDGAR2Form 8-K - Current report
28/2/202415:14EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202414:08EDGAR2Form 8-K - Current report
28/2/202414:00GLOBEvTv Therapeutics Announces $51 Million Private Placement..
22/2/202422:00PRNUSCANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO &..
22/12/202322:26EDGAR2Form 8-K - Current report
19/12/202322:28EDGAR2Form 8-K - Current report
12/12/202322:21EDGAR2Form 8-K - Current report
20/11/202322:23EDGAR2Form 8-K - Current report
15/11/202314:22EDGAR2Form 8-K - Current report
15/11/202314:19EDGAR2Form 8-K - Current report
09/11/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:30GLOBEvTv Therapeutics Announces 2023 Third Quarter Financial..
09/11/202322:20EDGAR2Form 8-K - Current report
08/11/202314:00GLOBEvTv Therapeutics to Participate at the Stifel 2023..
02/11/202313:00GLOBEvTv Therapeutics Appoints Thomas Strack, M.D., as Chief..
01/11/202313:24EDGAR2Form 8-K - Current report
01/11/202313:00GLOBEvTv Therapeutics Announces Sale of Shares in Reneo..
27/9/202314:30PRNUSCANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A..
26/9/202314:30PRNUSCantex and Allegheny Health Network Announce Initiation of a..
25/9/202322:20EDGAR2Form DEF 14C - Other definitive information statements
18/9/202314:30PRNUSCANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE..
15/9/202322:17EDGAR2Form PRE 14C - Other preliminary information statements
11/8/202322:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202322:36EDGAR2Form 8-K - Current report
11/8/202322:30GLOBEvTv Therapeutics Announces 2023 Second Quarter Financial..
10/8/202314:33PRNUSCantex Pharmaceuticals Announces Article Published in npj..
20/7/202322:22EDGAR2Form 8-K - Current report
16/6/202314:00GLOBEvTv Therapeutics Partner Cantex Pharmaceuticals Licenses..
15/6/202313:33PRNUSCANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY..
24/5/202315:00GLOBEvTv Therapeutics Announces Issuance of U.S. Patent for..
11/5/202322:15GLOBEvTv Therapeutics Announces 2023 First Quarter Financial..

Dernières Valeurs Consultées

NASDAQ
VTVT
vTv Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés